Latest Breaking News On - மருத்துவமனை புற்றுநோய் மையம் - Page 6 : comparemela.com

New option in radiation treatment begins at AR Gould Hospital

SH-argould1-0407-21 Dr. Charles Hechtman, radiation oncologist at AR Gould Hospital, checks on patient Jerry Boulier after he receives one of his SBRT treatments at the hospital. He is the first patient to be treated by SBRT at the hospital. (Courtesy of AR Gould Hospital) Dr. Charles Hechtman, radiation oncologist at AR Gould Hospital, checks on patient Jerry Boulier after he receives one of his SBRT treatments at the hospital. He is the first patient to be treated by SBRT at the hospital. (Courtesy of AR Gould Hospital) New option in radiation treatment begins at AR Gould Hospital Contributed • April 14, 2021

United statesDana farber cancer instituteFort fairfieldJerry boulierCharles hechtmanHospital cancer centerNorthern lightBrice hamiltonCancer careNorthern light cancer careMassachusetts general hospital cancer centerஒன்றுபட்டது மாநிலங்களில்டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம்கோட்டை ஃபேர்ஃபீல்ட்சார்லஸ் ஹெட்ச்மேன்மருத்துவமனை புற்றுநோய் மையம்

Another FGFR Inhibitor Active in Bile Duct Cancers

email article More than 40% of patients with advanced cholangiocarcinoma (CCA) had objective responses that were durable in most cases following treatment with a multitargeted fibroblast growth factor receptor (FGFR) inhibitor, a preliminary study showed. Treatment with the investigational agent futibatinib led to an overall response rate (ORR) of 41.7% in 103 patients and a median duration of response of 9.7 months. Another 40% of the patients had stable disease. Median overall survival (OS) approached 2 years, and 72% of the patients were alive at 12 months, reported Lipika Goyal, MD, of Massachusetts General Hospital Cancer Center in Boston, at the American Association for Cancer Research (AACR) virtual meeting.

United statesEzra cohenLipika goyalCharles bankheadPemigatinib pemazyreUniversity of california san diegoAmerican association for cancer researchHospital cancer centerMoores cancer centerMassachusetts general hospital cancer centerAmerican associationCancer researchCalifornia san diegoMedpage todayஒன்றுபட்டது மாநிலங்களில்எஸ்ரா கோஹன்

Taiho Oncology Announces Presentation of Phase 2 Data for Futibatinib (TAS-120) in Advanced Intrahepatic Cholangiocarcinoma at Virtual AACR Annual Meeting 2021

Share this article Share this article PRINCETON, N.J., April 11, 2021 /PRNewswire/ Taiho Oncology, Inc. today announced efficacy and safety results from the Phase 2 FOENIX-CCA2 trial, a single-arm multicenter Phase 2 study evaluating futibatinib (TAS-120) in patients with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene rearrangements including gene fusions who have failed at least one line of therapy. The data were presented online as an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021 Week 1 Clinical Trials Plenary from 2:00 – 3:45 PM ET on April 11, 2021. In the FOENIX-CCA2 trial, 103 patients with locally advanced or metastatic unresectable iCCA harboring FGFR2 gene rearrangements including fusions who had received one or more prior lines of systemic therapy received futibatinib 20 mg once daily until disease progression or unacceptable toxicity. The study met its primary endpoint of a greater than 20% object

United statesIkuo yamamiyaMartinj birkhoferHiroshi sootomeCraig heitLipika goyalOffice of orphan drug developmentTaiho pharmaceutical co ltdHospital cancer centerDrug administrationTranslational research planning managementTaiho oncology incAmerican association for cancer researchCholangiocarcinoma foundationOtsuka holdings co ltdAmerican cancer society

Cardiff Oncology in Collaboration with MIT Presents Gene Signature Analyses Data Identifying Androgen-Independent Mechanism for Onvansertib-Abiraterone Synergy in mCRPC

Share this article SAN DIEGO, April 10, 2021 /PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer, in collaboration with scientists in the Center for Precision Cancer Medicine at the Massachusetts Institute of Technology (MIT), today announced that new gene signature and mechanistic analyses related to its ongoing Phase 2 trial of onvansertib in metastatic castrate-resistant prostate cancer (mCRPC) were featured in a virtual oral poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021.

Dana farber cancer instituteUnited statesMassachusetts institute of technologyDavidh kochMichaelb yaffeDavid einsteinKatelyn caruso sharpeMark erlanderVicki kelemenJoyce allaireCardiff oncology incHospital cancer centerBeth israel deaconess medical centerPrnewswire cardiff oncology incExchange commissionGenitourinary oncology program

North America Patient Registry Software Market Size, Share, Demand, Analysis and Forecast To 2027 | CEDARON, Evado Clinical, FIGmd Inc , Global Vision Technologies, Inc

North America Patient Registry Software Market Size, Share, Demand, Analysis and Forecast To 2027 | CEDARON, Evado Clinical, FIGmd Inc , Global Vision Technologies, Inc
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesRush university medical centerAmerica patient registry software marketGlobal vision technologies incMedia telecommunicationsSemiconductor electronicsFigmd incAmerica patient registry softwareText corporationAerospace defenseResearch newswireOpen text corporationDoorn corporationOptum incPatient registry software